Glioblastoma multiforme (GBM)<\/a> is the most aggressive form of primary brain tumours. Forty to fifty percent of primary central nervous system tumours are gliomas and, of these, 50% are GBMs. Grade IV gliomas grow rapidly, invading the brain causing death within 3 months if no appropriate treatment is administered. In order to induce significant cell killing in these aggressive tumours, drugs capable of blocking targets are required. Our laboratory has now designed and synthesized such type of drugs directed at proteins termed EGFR, EGFRvIII, Src that drive tumour progression and reduce tumour sensitivity to chemotherapeutic drugs.<\/p>\nIn order to block the progression of these aggressive tumours, novel type of multitargeted molecules are urgently needed. Our laboratory has now designed and synthesize such type of molecules termed \u201ccombi-molecules\u201d. The purpose of this proposal is to study their ability to penetrate into the brain and to strike the tumours at multiple targets (e.g. EGFR, EGFRvIII, Src) that shield them against the effects of chemotherapeutic drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: \u00ab\u00a0Brain penetrability and in vivo potency of novel multi-targeted combi-drugs\u00a0\u00bb<\/p>\n","protected":false},"featured_media":2256,"menu_order":0,"template":"","research_recipient_type":[285],"class_list":["post-4774","research_recipients","type-research_recipients","status-publish","has-post-thumbnail","hentry","research_recipient_type-grant-fr"],"acf":[],"yoast_head":"\n
Dr. Jean-Claude Bertrand - Subvention de recherche 2011 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales<\/title>\n<meta name=\"description\" content=\"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: "Brain penetrability and in vivo potency of novel multi-targeted combi-drugs"\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Jean-Claude Bertrand - Subvention de recherche 2011\" \/>\n<meta property=\"og:description\" content=\"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: "Brain penetrability and in vivo potency of novel multi-targeted combi-drugs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation canadienne des tumeurs c\u00e9r\u00e9brales\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-20T23:08:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"595\" \/>\n\t<meta property=\"og:image:height\" content=\"448\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/\",\"url\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/\",\"name\":\"Dr. Jean-Claude Bertrand - Subvention de recherche 2011 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales\",\"isPartOf\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg\",\"datePublished\":\"2011-04-21T19:25:04+00:00\",\"dateModified\":\"2020-05-20T23:08:14+00:00\",\"description\":\"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: \\\"Brain penetrability and in vivo potency of novel multi-targeted combi-drugs\\\"\",\"breadcrumb\":{\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage\",\"url\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg\",\"contentUrl\":\"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg\",\"width\":595,\"height\":448,\"caption\":\"Dr. Jean-Claude Bertrand\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.braintumour.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Recipients\",\"item\":\"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Dr. Jean-Claude Bertrand – Subvention de recherche 2011\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.braintumour.ca\/fr\/#website\",\"url\":\"https:\/\/www.braintumour.ca\/fr\/\",\"name\":\"Fondation canadienne des tumeurs c\u00e9r\u00e9brales\",\"description\":\"Notre mission est de venir en aide \u00e0 toutes les personnes touch\u00e9es par une tumeur c\u00e9r\u00e9brale au Canada par le biais de nos programmes d\u2019information, de soutien, d\u2019\u00e9ducation et de recherche.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.braintumour.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dr. Jean-Claude Bertrand - Subvention de recherche 2011 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales","description":"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: \"Brain penetrability and in vivo potency of novel multi-targeted combi-drugs\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/","og_locale":"fr_CA","og_type":"article","og_title":"Dr. Jean-Claude Bertrand - Subvention de recherche 2011","og_description":"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: \"Brain penetrability and in vivo potency of novel multi-targeted combi-drugs\"","og_url":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/","og_site_name":"Fondation canadienne des tumeurs c\u00e9r\u00e9brales","article_modified_time":"2020-05-20T23:08:14+00:00","og_image":[{"width":595,"height":448,"url":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/","url":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/","name":"Dr. Jean-Claude Bertrand - Subvention de recherche 2011 - Fondation canadienne des tumeurs c\u00e9r\u00e9brales","isPartOf":{"@id":"https:\/\/www.braintumour.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage"},"image":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage"},"thumbnailUrl":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg","datePublished":"2011-04-21T19:25:04+00:00","dateModified":"2020-05-20T23:08:14+00:00","description":"Dr. Jean-Claude Bertrand, Royal Victoria Hospital\/McGill University. Project: \"Brain penetrability and in vivo potency of novel multi-targeted combi-drugs\"","breadcrumb":{"@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#primaryimage","url":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg","contentUrl":"https:\/\/www.braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC.jpg","width":595,"height":448,"caption":"Dr. Jean-Claude Bertrand"},{"@type":"BreadcrumbList","@id":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/dr-jean-claude-bertrand-research-grant-2011\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.braintumour.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Research Recipients","item":"https:\/\/www.braintumour.ca\/fr\/laureats_de_la_recherche\/"},{"@type":"ListItem","position":3,"name":"Dr. Jean-Claude Bertrand – Subvention de recherche 2011"}]},{"@type":"WebSite","@id":"https:\/\/www.braintumour.ca\/fr\/#website","url":"https:\/\/www.braintumour.ca\/fr\/","name":"Fondation canadienne des tumeurs c\u00e9r\u00e9brales","description":"Notre mission est de venir en aide \u00e0 toutes les personnes touch\u00e9es par une tumeur c\u00e9r\u00e9brale au Canada par le biais de nos programmes d\u2019information, de soutien, d\u2019\u00e9ducation et de recherche.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.braintumour.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"}]}},"_links":{"self":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipients\/4774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipients"}],"about":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/types\/research_recipients"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/media\/2256"}],"wp:attachment":[{"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/media?parent=4774"}],"wp:term":[{"taxonomy":"research_recipient_type","embeddable":true,"href":"https:\/\/www.braintumour.ca\/fr\/wp-json\/wp\/v2\/research_recipient_type?post=4774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"Dr.](\"https:\/\/braintumour.ca\/wp-content\/uploads\/2019\/11\/photo-BJC-300x226.jpg\")
Glioblastoma multiforme (GBM)<\/a> is the most aggressive form of primary brain tumours. Forty to fifty percent of primary central nervous system tumours are gliomas and, of these, 50% are GBMs. Grade IV gliomas grow rapidly, invading the brain causing death within 3 months if no appropriate treatment is administered. In order to induce significant cell killing in these aggressive tumours, drugs capable of blocking targets are required. Our laboratory has now designed and synthesized such type of drugs directed at proteins termed EGFR, EGFRvIII, Src that drive tumour progression and reduce tumour sensitivity to chemotherapeutic drugs.<\/p>\n